Bibliografía
[1] E. Longinetti and F. Fang, “Epidemiology of amyotrophic lateral sclerosis: an update of recent literature,” Curr. Opin. Neurol., vol. 32, no. 5, Oct. 2019, doi: 10.1097/WCO.0000000000000730.
[2] P. Mehta et al., “Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016,” Amyotroph. Lateral Scler. Front. Degener., Aug. 2021, doi: 10.1080/21678421.2021.1949021.
[3] S. L. James et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017,” Lancet, vol. 392, no. 10159, pp. 1789–1858, Nov. 2018, doi: 10.1016/S0140-6736(18)32279-7.
[4] INCN. (2011). PLAN ESTRATÉGICO INSTITUCIONAL 2010-2011[Online]. Available: https://www.peru.gob.pe/docs/PLANES/13258/PLAN_13258_Plan_Estrat%C3%A9gico_Institucional_2011.pdf
[5] G. Logroscino et al., “Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016,” The Lancet Neurology, doi: 10.1016/s1474-4422(18)30404-6.
[6] “Revista DIAGNÓSTICO,” Fihu.org.pe, 2021. http://www.fihu.org.pe/revista/numeros/2009/ene-mar/7-12.html
[7] “ALS ASSOCIATION.” https://www.als.org/ (accessed Sep. 10, 2021).
[8] “Asociación ELA Perú.” https://elaperu.org/ (accessed Sep. 10, 2021).
[9] MINSAL. (2017). INFORME DE EVALUACIÓN CIENTÍFICA BASADA EN LA EVIDENCIA DISPONIBLE [Online]. Available: https://www.minsal.cl/wp-content/uploads/2017/10/ELA.pdf
[10] J. P. Rosa Silva, J. B. Santiago Júnior, E. L. dos Santos, F. O. de Carvalho, I. M. P. de França Costa, and D. M. F. de Mendonça, “Quality of life and functional independence in amyotrophic lateral sclerosis: A systematic review,” Neurosci. Biobehav. Rev., vol. 111, Apr. 2020, doi: 10.1016/j.neubiorev.2019.12.032.
[11] J. de Wit et al., “Caregiver burden in amyotrophic lateral sclerosis: A systematic review,” Palliat. Med., vol. 32, no. 1, Jan. 2018, doi: 10.1177/0269216317709965.
[12] K. Achtert and L. Kerkemeyer, “The economic burden of amyotrophic lateral sclerosis: a systematic review,” Eur. J. Heal. Econ., Jun. 2021, doi: 10.1007/s10198-021-01328-7.
[13] “Overview of current and emerging therapies for amytrophic lateral sclerosis,” Am. J. Manag. Care, vol. 26, no. Suppl 9, Aug. 2020, doi: 10.37765/ajmc.2020.88483.
[14] Štětkářová, I., & Ehler, E. (2021). Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date. Diagnostics, 11(2), 231.
